Basilea Pharmaceutica AG/€BSLN
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a biopharmaceutical company headquartered in Basel, Switzerland. The company focuses on the research, development, and commercialization of innovative medicines, primarily in the areas of infectious diseases and oncology. Some of its key products include antifungal and antibiotic treatments like Cresemba and Zevtera, which address significant medical needs in their respective markets. Basilea was founded as a spin-off from Roche in 2000, reflecting its strong roots in pharmaceutical research. The company's strategic positioning capitalizes on its expertise in addressing drug-resistant bacterial infections and rare fungal infections, providing solutions where few alternatives exist. Basilea operates on a global scale, collaborating with international partners to expand its research and market reach.
Ticker
€BSLN
Sector
Primary listing
XGAT
Employees
180
Headquarters
Allschwil, Switzerland
Website
BSLN Metrics
BasicAdvanced
€608M
8.59
€5.77
0.71
-
Price and volume
Market cap
€608M
Beta
0.71
52-week high
€63.10
52-week low
€40.00
Average daily volume
25K
Financial strength
Current ratio
6.323
Quick ratio
5.399
Long term debt to equity
91.826
Total debt to equity
93.825
Interest coverage (TTM)
20.43%
Profitability
EBITDA (TTM)
83.637
Gross margin (TTM)
46.39%
Net profit margin (TTM)
30.76%
Operating margin (TTM)
32.51%
Effective tax rate (TTM)
-0.52%
Revenue per employee (TTM)
€1,399,450
Management effectiveness
Return on assets (TTM)
21.88%
Return on equity (TTM)
121.16%
Valuation
Price to earnings (TTM)
8.589
Price to revenue (TTM)
2.394
Price to book
5.52
Price to tangible book (TTM)
5.54
Price to free cash flow (TTM)
7.268
Free cash flow yield (TTM)
13.76%
Free cash flow per share (TTM)
6.818
Growth
Revenue change (TTM)
58.51%
Earnings per share change (TTM)
-10,210.70%
3-year revenue growth (CAGR)
15.94%
10-year revenue growth (CAGR)
17.51%
3-year earnings per share growth (CAGR)
323.60%
10-year earnings per share growth (CAGR)
0.51%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Basilea Pharmaceutica AG stock?
Basilea Pharmaceutica AG (BSLN) has a market cap of €608M as of August 29, 2025.
What is the P/E ratio for Basilea Pharmaceutica AG stock?
The price to earnings (P/E) ratio for Basilea Pharmaceutica AG (BSLN) stock is 8.59 as of August 29, 2025.
Does Basilea Pharmaceutica AG stock pay dividends?
No, Basilea Pharmaceutica AG (BSLN) stock does not pay dividends to its shareholders as of August 29, 2025.
When is the next Basilea Pharmaceutica AG dividend payment date?
Basilea Pharmaceutica AG (BSLN) stock does not pay dividends to its shareholders.
What is the beta indicator for Basilea Pharmaceutica AG?
Basilea Pharmaceutica AG (BSLN) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.